Compounds > lonafarnib
Page last updated: 2024-09-04

lonafarnib and Vomiting

lonafarnib has been researched along with Vomiting in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bishop, WR; Cleveland, R; Correia, A; Fligor, B; Gerhard-Herman, M; Giobbie-Hurder, A; Gordon, CM; Gordon, LB; Huh, SY; Kieran, MW; Kleinman, ME; Liang, MG; Miller, DT; Nazarian, A; Neuberg, DS; Ploski, C; Quinn, N; Regen, A; Riley, S; Schwartzman, A; Smoot, LB; Snyder, BD; Sonis, A; Statkevich, P; Ullrich, NJ1
Cortes, J; Daley, GQ; Ferrajoli, A; Jabbour, E; Kantarjian, H; Koller, C; O'Brien, S; Statkevich, P; Verstovsek, S; Zhu, Y1
Basche, M; Chow, LQ; Eckhardt, SG; Gore, L; Grolnic, S; Morrow, M; O'Bryant, CL; Schultz, MK1

Trials

3 trial(s) available for lonafarnib and Vomiting

ArticleYear
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
    Proceedings of the National Academy of Sciences of the United States of America, 2012, Oct-09, Volume: 109, Issue:41

    Topics: Adolescent; Carotid Arteries; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Piperidines; Progeria; Pulse Wave Analysis; Pyridines; Treatment Outcome; Vomiting; Weight Gain

2012
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cancer, 2007, Sep-15, Volume: 110, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Vomiting

2007
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Gemcitabine; HSP40 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Piperidines; Pyridines; Treatment Outcome; Vomiting

2008